low - Organ transplantation is non-discretionary medical care driven by clinical need rather than economic conditions. Hospital capital budgets for transplant programs are relatively insulated from GDP fluctuations given the life-saving nature and reimbursement stability. However, severe recessions could delay hospital capital equipment purchases, though NOP service model mitigates this risk by eliminating upfront hospital investment.

Rising interest rates create moderate headwinds through two channels: (1) higher cost of capital for hospital systems evaluating OCS console purchases, potentially accelerating NOP adoption but slowing direct equipment sales, and (2) valuation multiple compression for high-growth, unprofitable medtech stocks as investors demand higher risk premiums. The company's 1.46 debt/equity ratio suggests manageable financing cost exposure, but negative free cash flow makes equity financing costs relevant for growth capital.

growth - The stock attracts growth investors focused on disruptive medtech with large addressable markets. The 82.7% revenue growth, 241.7% net income growth, and early-stage profitability appeal to investors willing to accept negative free cash flow for market share capture. The 80.6% one-year return and 8.2x price/sales ratio reflect growth premium valuation. Momentum investors also participate given strong recent performance, while the 31.4% ROE attracts GARP (growth at reasonable price) investors as profitability scales.